10x Genomics Inc. has published the transcript of its Third Quarter 2025 earnings call, which featured remarks from the CEO and Co-Founder, Serge Saxonov, and Chief Financial Officer, Adam Taich, along with Cassie Corneau, Senior Director, Head of Investor Relations and Strategic Finance. The event focused on the company's latest financial results and strategic initiatives. During the call, management discussed the evolving spatial biology landscape and highlighted the strong, growing preference for image-based analysis, specifically noting the success of the Xenium platform. "We now see a strong and growing preference for image-based analysis. This is a reflection of both how well Xenium works and the abundance of insights that scientists are gaining from using the platform," said one executive. The company also emphasized opportunities in translational research and clinical applications, referencing a recent collaboration with CLISEQ and the Weizmann Institute on the PERIBLOOD clinical trial, which leverages single-cell technology for the detection of hematologic disorders. Management cautioned that forward-looking statements made during the call involve material risks and uncertainties, and actual results may differ from those anticipated. The full transcript can be accessed through the link below.